MetaCap

BeOne Medicines (ONC) vs Viatris (VTRS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Viatris (VTRS) has outperformed BeOne Medicines (ONC) over the past year, gaining 87.7% versus a gain of 12.4%. Over five years, VTRS leads with a +54.0% price change compared with +12.4% for ONC. BeOne Medicines is the larger company by market cap ($44.66 billion vs $22.50 billion), about 2.0 times the size.

On valuation, Viatris trades at a lower forward P/E (6.9x vs 35.9x for BeOne Medicines). Viatris pays a dividend yielding 2.45%, while BeOne Medicines does not currently pay one. BeOne Medicines converts more of its revenue into profit, with a net margin of 5.4% versus -24.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ONC+12.43%VTRS+87.67%
+108%+38%-31%
Nov 21, 20251 yearNov 20, 2026
ONC+7.24%VTRS+50.08%
+65%-3%-71%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ONC versus VTRS key metrics
MetricONCVTRS
Share price$390.94$19.63
Market cap$44.66B$22.50B
1-day change-2.19%-1.26%
YTD return+28.68%+57.67%
1-year return+12.43%+87.67%
5-year return+12.44%+53.96%
P/E ratio (TTM)50.12—
Forward P/E35.936.94
EPS (TTM)$7.80$-0.53
Dividend yield0.00%2.45%
Annual dividend$0.00$0.48
Revenue (latest FY)$5.34B$14.30B
Revenue growth (YoY)+40.23%-2.98%
Net income (latest FY)$286.93M$-3.51B
Gross margin87.49%35.06%
Operating margin8.37%-18.62%
Net margin5.37%-24.58%
52-week high$424.73$21.20
52-week low$253.95$10.39
Distance from 52-week high-7.96%-7.41%
Analyst consensusstrong_buybuy
Avg. price target upside+20.03%+10.04%
Average volume392.74K9.11M
Shares outstanding105.38M1.15B
Employees12,00030,000
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • VTRS has outperformed ONC by 75.2 percentage points over the past year.
  • Viatris offers a meaningfully higher dividend yield (2.45% vs 0.00%).
  • BeOne Medicines is more profitable, keeping 5.4 cents of every revenue dollar as net income versus -24.6 cents for Viatris.
  • BeOne Medicines grew revenue faster in its latest fiscal year (+40.23% vs -2.98%).

About BeOne Medicines

ONC stock →

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 12,000 employees

About Viatris

VTRS stock →

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets.

Health Care · Biotechnology: Pharmaceutical Preparations · 30,000 employees

ONC vs VTRS FAQ

Which is bigger, BeOne Medicines or Viatris?

BeOne Medicines (ONC) is larger, with a market capitalization of $44.66B compared with $22.50B for Viatris (VTRS).

Which stock has performed better over the past year, ONC or VTRS?

VTRS returned +87.67% over the past 12 months, compared with +12.43% for ONC (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, BeOne Medicines or Viatris?

Viatris pays a dividend yielding 2.45%, while BeOne Medicines does not currently pay a regular dividend.

Are BeOne Medicines and Viatris in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons